Company Overview

lmmuDyne, Inc. (OTCQB: IMMD) is a health and wellness company that develops, manufactures, and commercializes innovative products that address large unmet needs in the marketplace. At present, Immudyne is commercializing three products and anticipates adding at least one proprietary product to its portfolio in 2017.

Immudyne’s products are proprietary, patented, and clinically researched Yeast Beta-1,3/1,6-D-glucans, for both topical and oral applications. Immudyne sells these strategic, raw ingredients to top tier cosmetic and nutritional companies. Yeast Beta-1,3/1,6-D-glucan has been shown in thousands of clinical studies to be a powerful immune modulator with potent anti-oxidant properties. In skincare, clinical studies have demonstrated that topical Yeast Beta-1,3/1,6-D-glucan stimulates Langerhans cells (the skin’s immune system) and has anti-aging properties.

In early 2016 Immudyne launched Inate MD, a complete skincare system containing its Yeast Beta-1,3/1,6 D-glucan, along with several other highly potent, clinically studied anti-aging ingredients. Inate MD is the only skincare line on the market built around stimulation of the human immune system to improve skin health and appearance. Through Q3, $4.25MM in revenue was generated through sales of Inate MD products. Immudyne anticipates continued growth of this product line in 2017 and beyond.

Our third product, Shapiro MD, is a patented, all-natural shampoo and conditioner for hair loss. We plan on launching the Shapiro MD product line in Q1 2017 and anticipate that it will meaningfully contribute to 2017 revenue.

In 2016, Immudyne grew its business by over 300% to top line revenue of $4.25 MM though Q3, the highest in its history. Most importantly, Immudyne committed significant resources in 2016 to building a world-class direct-marketing infrastructure which will be used to profitably grow all three of our brands in 2017.


  • 70% top-line growth in 2015; over 300% top-line growth through Q3 of 2016
  • Emerging revenue and customer acquisition model
  • Reasonable cash position and conservative monthly overhead
  • Endorsements in 2016 from opinion-leading Dermatologists
  • Product portfolio that addresses very large, multi-billion dollar markets
  • 34M shares outstanding as of 12/31/2016
  • Talented leadership team with strong track record creating shareholder value

Investor Presentation

Our latest corporate presentation


Stock Snapshot

IMMD Symbol
OTCQB Market
Market Cap